Targeting tumour-associated macrophages in hodgkin lymphoma using engineered extracellular matrix-mimicking cryogels

Tumour-associated macrophages are linked with poor prognosis and resistance to therapy in Hodgkin lymphoma; however, there are no suitable preclinical models to identify macrophage-targeting therapeutics. We used primary human tumours to guide the development of a mimetic cryogel, wherein Hodgkin (but not Non-Hodgkin) lymphoma cells promoted primary human macrophage invasion. In an invasion inhibitor screen, we identified five drug hits that significantly reduced tumour-associated macrophage invasion: marimastat, batimastat, AS1517499, ruxolitinib, and PD-169316. Importantly, ruxolitinib has demonstrated recent success in Hodgkin lymphoma clinical trials. Both ruxolitinib and PD-169316 (a p38 mitogen-activated protein kinase (p38 MAPK) inhibitor) decreased the percent of M2-like macrophages; however, only PD-169316 enhanced the percentage of M1-like macrophages. We validated p38 MAPK as an anti-invasion drug target with five additional drugs using a high-content imaging platform. With our biomimetic cryogel, we modeled macrophage invasion in Hodgkin lymphoma and then used it for target discovery and drug screening, ultimately identifying potential future therapeutics.

 

Comments：

The researchers found that two of the drug hits, ruxolitinib and PD-169316, decreased the percentage of M2-like macrophages. M2-like macrophages are known to be pro-tumorigenic and associated with poor prognosis and therapy resistance in Hodgkin lymphoma. However, only PD-169316 enhanced the percentage of M1-like macrophages, which are known to have anti-tumor activity.

The researchers validated p38 MAPK as an anti-invasion drug target using five additional drugs with a high-content imaging platform. Overall, this study provides a promising approach for identifying potential therapeutics for targeting tumor-associated macrophages in Hodgkin lymphoma.

Related Products

Cat.No.	Product Name	Information
S7155	Batimastat (BB-94)	Batimastat (BB-94) is a potent, broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-1, MMP-2, MMP-9, MMP-7 and MMP-3 with IC50 of 3 nM, 4 nM, 4 nM, 6 nM and 20 nM, respectively. Also inhibits the activitity of other metalloproteases, such as ADAM17.

Related Targets

MMP